Happening today ‼️ @TheEndoSociety

This Sunday, 7/13‼️Our CEO @JamesPeyer is headed to @TheEndoSociety to present new data on the efficacy of ATX-304, our lead drug. Check out the press release to learn more 👇 https://t.co/dykERwYSwT

One of the most hollow critiques of translating discoveries about aging biology – “they will only be for the rich.” Demand curve says no. Preventative medicines are cheaper than other drugs and these will be among the best preventatives of all time. https://t.co/KGeOLdukKE

This newsletter is meant to be my own thinking and I try to be a bit more provocative here, so the views I express might not always reflect the position of @CambrianBio, which is much larger than me alone. https://t.co/DTJWKjxwXM

You can learn more about the historical disparities of women’s health on the @OvivaTx website. While you're there, be sure to explore the incredible work they're doing to improve women’s health through groundbreaking biomedical research!

But today, as we celebrate women and the progress made, let's remember that our work isn't done. We must continue pushing for a future where women's health is prioritized, ensuring that every woman receives the care she deserves.

• In 2018, only 15% of the NIH budget was allocated to all of women’s health. These gaps have led to poorer health outcomes for women across all aspects of healthcare.

• It wasn’t until 1993 that inclusion of both sexes was required in clinical trials in the U.S. • Up until 2016, when the NIH mandated both sexes be included in all studies of grant recipients, biomedical research had been conducted primarily in male animals.

Happy International Women’s day! Here are some fun facts about women’s health 👇

While we don't endorse chasing people down for snacks, our goal is to enable everyone to live as Dyna-Mitally through later years! 😉 #DinamitaDinero

Awesome news from our friends at @bioagelabs, congratulations!

To learn more about ATX-304 check out this blog by James:

Check out the full interview for free here:

Here’s what our CEO @JamesPeyer had to say about that question when talking with Diane Brady of @Forbes about all things Cambrian, but more specifically about ATX-304, the pan-AMPK activator, being developed by our pipeline company Amplifier Therapeutics.

Do you consider the potential impact of medical interventions on individuals' motivation to make difficult lifestyle changes, particularly in cases such as #obesity, where lifestyle changes are challenging but essential for improving health outcomes? 👇

This news is incredibly disheartening for the entire field and those personally impacted by her. We can only aspire, as a community, to build on the foundation she was instrumental in fortifying. May she rest in peace.

She gained widespread recognition for her extensive research on the impact of senescent cells on aging and cancer. Despite facing numerous challenges, she dedicated years to the pursuit of this research, and the data she generated is now acclaimed as a hallmark of aging. (Cont.)

It is with great sadness that we share that this week we learned about the passing of Judith Campisi, who was, amongst many other wonderful things, a pioneer in the aging space. (Cont.)

Check out the full article for a deeper understanding of these complexities, as well as for some insights from leaders in the space.

(including #mTOR inhibitors, such as those pursued by our pipeline company, Tornado Therapeutics). The article also explores barriers to progress and issues a cautionary note about the 'hype' surrounding less scientifically rigorous aspects of our field.